UY32688A - 17B(BETA)-ALQUIL-17a(ALFA)-OXI-ESTRATRIENOS - Google Patents

17B(BETA)-ALQUIL-17a(ALFA)-OXI-ESTRATRIENOS

Info

Publication number
UY32688A
UY32688A UY0001032688A UY32688A UY32688A UY 32688 A UY32688 A UY 32688A UY 0001032688 A UY0001032688 A UY 0001032688A UY 32688 A UY32688 A UY 32688A UY 32688 A UY32688 A UY 32688A
Authority
UY
Uruguay
Prior art keywords
beta
estratrienos
alquil
oxi
alfa
Prior art date
Application number
UY0001032688A
Other languages
English (en)
Inventor
Dr Michael Gerisch
Dr Rolf Bohlmann
Dr Nikolaus Heinrich
Dr Jan Huebner
Dr Georg Kettschau
Dr Hermann Kuenzer
Dr Philip Lienau
Dr Silke Mueller
Dr Dieter Lang
Dr Karsten Denner
Dr Michael Sander
Dr Jens Hoffmann
Dr Tim Wintermantel
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41460961&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY32688(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of UY32688A publication Critical patent/UY32688A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C07C215/30—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

17b(beta)-alquil-17a(alfa)-oxi-estratrienos de fórmula (I), procesos para prepararlos, el uso de los 17b(beta)-alquil-17a(alfa)-oxi-estratrienos para preparar fármacos y preparaciones farmacéuticas que comprenden estos compuestos.
UY0001032688A 2009-06-04 2010-06-03 17B(BETA)-ALQUIL-17a(ALFA)-OXI-ESTRATRIENOS UY32688A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09075249A EP2258375A1 (de) 2009-06-04 2009-06-04 17B-alkyl-17alpha-oxy-estratriene

Publications (1)

Publication Number Publication Date
UY32688A true UY32688A (es) 2010-12-31

Family

ID=41460961

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032688A UY32688A (es) 2009-06-04 2010-06-03 17B(BETA)-ALQUIL-17a(ALFA)-OXI-ESTRATRIENOS

Country Status (27)

Country Link
US (1) US20120157421A1 (es)
EP (2) EP2258375A1 (es)
JP (1) JP2012528808A (es)
KR (1) KR20120042827A (es)
CN (1) CN102802634A (es)
AR (1) AR076980A1 (es)
AU (1) AU2010256035A1 (es)
BR (1) BRPI1013017A2 (es)
CA (1) CA2764249A1 (es)
CL (1) CL2011003050A1 (es)
CO (1) CO6470855A2 (es)
CR (1) CR20110647A (es)
CU (1) CU20110224A7 (es)
DO (1) DOP2011000374A (es)
EA (1) EA201101703A1 (es)
EC (1) ECSP11011501A (es)
IL (1) IL216524A0 (es)
MA (1) MA33329B1 (es)
MX (1) MX2011012878A (es)
NZ (1) NZ596824A (es)
PE (1) PE20120318A1 (es)
SG (1) SG176630A1 (es)
TN (1) TN2011000617A1 (es)
TW (1) TW201103547A (es)
UY (1) UY32688A (es)
WO (1) WO2010139411A2 (es)
ZA (1) ZA201200036B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116041412A (zh) * 2023-01-13 2023-05-02 香港中文大学（深圳） 氟维司群衍生物及其制备方法、应用和治疗乳腺癌的药物
CN116535454A (zh) * 2023-04-28 2023-08-04 香港中文大学（深圳） 氟维司群类化合物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
EP0310542B1 (de) 1987-10-01 1994-06-08 Schering Aktiengesellschaft Antigestagen- und antiöstrogenwirksame Verbindungen zur Behandlung hormonabhängiger Tumoren
GB8813353D0 (en) 1988-06-06 1988-07-13 Ici Plc Therapeutic product
DE19510862A1 (de) 1995-03-16 1996-09-19 Schering Ag Verwendung von Antiestrogenen zur männlichen Fertilitätskontrolle
DE19622457A1 (de) 1996-05-24 1997-11-27 Schering Ag 7alpha-(5-Methylaminopentyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha-(5-Methylaminopentyl)-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
DE19635525A1 (de) 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
AR015500A1 (es) 1997-12-23 2001-05-02 Schering Ag 11 BETA-HALoGENO-ESTRATRIENOS SUSTITUIDOS EN 7 ALFA, PROCEDIMIENTO PARA ELABORAR PREPARADOS FARMACEUTICOS QUE CONTIENEN TALES 11 BETA-HALOGENO-ESTRATRIENOSSUSTITUIDOS EN 7 ALFA, ASI COMO SU UTILIZACION EN LA ELABORACION DE MEDICAMENTOS.
DE10019171A1 (de) 2000-04-07 2001-10-18 Schering Ag Zusammensetzungen zur Verwendung als Penetrationsverstärker in transdermalen Formulierungen für hoch lipophile Wirkstoffe
DE10159217A1 (de) * 2001-11-27 2003-06-05 Schering Ag 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate

Also Published As

Publication number Publication date
AR076980A1 (es) 2011-07-20
CU20110224A7 (es) 2012-04-15
EP2437746A2 (de) 2012-04-11
ECSP11011501A (es) 2012-01-31
JP2012528808A (ja) 2012-11-15
NZ596824A (en) 2013-07-26
SG176630A1 (en) 2012-01-30
CR20110647A (es) 2012-02-16
EP2258375A1 (de) 2010-12-08
BRPI1013017A2 (pt) 2016-03-29
PE20120318A1 (es) 2012-03-24
CL2011003050A1 (es) 2012-06-15
DOP2011000374A (es) 2012-01-15
CO6470855A2 (es) 2012-06-29
WO2010139411A2 (de) 2010-12-09
TW201103547A (en) 2011-02-01
EA201101703A1 (ru) 2012-06-29
TN2011000617A1 (en) 2013-05-24
CN102802634A (zh) 2012-11-28
MX2011012878A (es) 2012-01-12
KR20120042827A (ko) 2012-05-03
ZA201200036B (en) 2013-06-26
IL216524A0 (en) 2012-02-29
US20120157421A1 (en) 2012-06-21
WO2010139411A3 (de) 2011-03-10
MA33329B1 (fr) 2012-06-01
AU2010256035A1 (en) 2011-12-22
CA2764249A1 (en) 2010-12-09

Similar Documents

Publication Publication Date Title
ECSP11011390A (es) Compuestos espiro-amidas sustituidas
CL2008003690A1 (es) Compuestos derivados de amonobenzamida; composicion farmceutica que comprende los compuestos; y uso para controlar parasitos.
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
ECSP13012519A (es) Compuestos sustituidos de benzamida
ECSP12012334A (es) Morfolinopirimidinas y su uso en terapia
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
CL2012002189A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos.
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
ECSP11011183A (es) Compuestos orgánicos
ECSP11011184A (es) Compuestos orgánicos
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
CL2013001338A1 (es) Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
CL2012003745A1 (es) Compuestos derivados de aminopirazoloquinazolinas, como inhibidores frente a la actividad fosforilante del receptor igf-1 localizado en membranas celulares; preparacion farmaceutica que los contiene; y su uso en el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
CL2012000921A1 (es) Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes.
CL2013000352A1 (es) Compuesto derivado de isoxazolina como agentes antiparasitarios; composicion farmaceutica o veterinaria que comprende el compuesto; uso del compuesto para preparar un medicamento.
PA8827101A1 (es) Derivados de indazoles sustituidos con fenilo o piridinilo
GT201200126A (es) Derivados de la cromenona con actividad anti-tumoral
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
CL2012003281A1 (es) Uso de compuestos específicos estimuladores y/o activadores de sgc; formulacion farmaceutica que comprende dichos compuestos; kit que comprende los compuestos, y uso para la prevencion y/o tratamiento de la esclerosis sistematica.
DOP2010000259A (es) Derivados heterociclicos de urea y metodos de uso de los mismos-211
UY30846A1 (es) Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
CL2008003041A1 (es) Compuestos derivados de acido boronico, inhibidores de proteasoma; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
UY32315A (es) Compuestos de piperidina y usos de los mismo-596
UY32674A (es) Derivados heterociclicos de la urea y sus metodos de empleo
UY31864A (es) Derivados de urea hetericíclica y métodos de uso de los mismos-332

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20190131